MAPT and Alzheimer disease: One model of dynamic biomarkers reflecting the progression of AD describes accumulation of β-amyloid leading to synaptic dysfunction, tau-related neurodegeneration, changes in brain structure, and, ultimately, cognitive dysfunction [22].